Menu Search
Equities

Moberg Pharma AB (publ)

  • Add to watchlist
  • Add to portfolio
  • Add an alert
MB8:MUN

Moberg Pharma AB (publ)

Actions
  • Price (EUR)0.8715
  • Today's Change0.017 / 1.93%
  • Shares traded--
  • 1 Year change+1.87%
  • Beta0.9539
Data delayed at least 15 minutes, as of Feb 10 2026 08:23 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Moberg Pharma AB (publ), formerly Moberg Derma AB (publ) is a Sweden-based pharmaceutical company. The Company is a pharmaceutical company in dermatology focused on the commercialization of proprietary drugs based on proven substances. Moberg Pharma AB (publ) develops MOB-015, the treatment of nail fungus. Its product portfolio includes products for the treatment of skin diseases, pain, the treatment of nails damaged by fungus or psoriasis, dry and damaged feet and range of products for several types of skin and scalp problems. The Company deals with development, manufacture, direct and indirect sale, marketing and licensing of pharmaceuticals, medical devices and skin care products as well as related activities.

  • Revenue in SEK (TTM)12.50m
  • Net income in SEK-257.79m
  • Incorporated2006
  • Employees6.00
  • Location
    Moberg Pharma AB (publ)Gustavslundsvagen 42, 5 tr.BROMMA 167 51SwedenSWE
  • Phone+46 852230700
  • Fax+46 87352029
  • Websitehttps://www.mobergpharma.se/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.